Anara

Quick links to important sections

Anara

Method of action: Laxative

Treatment option: Constipation, Proctitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anara

Property Description
Active ingredient Sodium Picosulfate (INN)
Form Oral solution, Tablet, Powder for solution
Pharmacological class Stimulant Laxative (Contact Laxative)
Common use Constipation relief, Bowel cleansing
Origin Synthetic

Anara is a trade name for a medicine whose core active ingredient is Sodium Picosulfate (INN), a synthetic compound classified within the broad pharmaceutical group of Laxatives. This medication is specifically designated as a Stimulant Laxative, primarily intended for oral administration to promote efficient bowel evacuation. Its use for short-term relief of constipation is supported by pharmacological data.


What Type of Medicine is Anara?

Sodium Picosulfate is classified as a Contact Laxative, a precise category that indicates its direct stimulating action on the colonic mucosa. The compound is a prodrug that remains inactive until it is metabolized by the indigenous bacteria in the large intestine. Once activated, the resulting compound directly stimulates colonic peristalsis. This highly targeted, local action is characterized by its chemical properties. This method of action ensures the therapeutic effect is concentrated where elimination occurs.


Composition and Available Forms of Anara

This medication is available in multiple common dosage forms, including a liquid oral solution, traditional tablets, and powder for oral solution. While available as a single-ingredient product, Sodium Picosulfate is often compounded as a combination product with other agents, particularly Magnesium oxide and Citric acid. This combined formulation is often the preferred type for bowel preparation because it creates a dual-action agent, adding the osmotic laxative effect of Magnesium citrate. This combination approach is designed to be well-tolerated while ensuring a predictable outcome for necessary medical procedures.

Regulatory References

  1. Bowel Preparation
  2. Sodium Picosulfate, Magnesium Oxide, and Anhydrous Citric Acid

What side effects are possible with Anara?

Possible Side Effects and Safety Information

Anara (sodium picosulfate, magnesium oxide, and anhydrous citric acid) is a colon preparation agent, and its use is associated with a specific set of adverse reactions resulting from its strong laxative effect.

Common and Clinically Significant Adverse Reactions

The most frequently reported adverse events are common gastrointestinal effects. Very Common reactions (affecting 1 in 10 people or more) include headache, nausea, abdominal pain, abdominal distension, and rectal discomfort. Common reactions (affecting 1 in 100 to 1 in 10 people) include vomiting, malaise, fatigue, dry mouth, thirst, and sleep disorder.

Serious adverse reactions are primarily linked to fluid and electrolyte imbalances caused by the extensive bowel cleansing process. These include the potential for severe dehydration and significant shifts in blood mineral levels, such as hyponatremia (low sodium) and hypokalemia (low potassium). In susceptible individuals, these imbalances can lead to serious complications such as seizures, cardiac arrhythmias (irregular heartbeat), and acute kidney injury (renal failure). Allergic reactions, including anaphylaxis, have also been reported.

Safety Restrictions and Contraindications

Anara is formally contraindicated in certain patient groups, including individuals with severe kidney disease (renal impairment), known or suspected gastrointestinal obstruction or perforation, gastric retention, or toxic megacolon. It is also not authorized for use in children or adolescents under 18 years of age.

Caution is advised for use in the elderly and in patients with pre-existing heart conditions, including heart failure or a prolonged QT interval, due to the increased risk of severe electrolyte disturbances and related complications. Official documentation stresses that exceeding the recommended dose or failing to mix the powder correctly increases the risk of severe dehydration and serious adverse effects.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile establishes that the primary presentation of acute overdose involves severe and profuse diarrhoea alongside intense abdominal cramps. This immediate manifestation leads to a clinically significant loss of fluid and essential electrolytes, primarily potassium, which can result in dehydration.

Overdosage may also occur chronically through laxative abuse, presenting a distinct syndrome characterized by persistent hypokalaemia, renal tubular damage, and metabolic alkalosis, as described in prescribing information.

The systemic risk of severe complications arises directly from these fluid and electrolyte disturbances. Documented, life-threatening outcomes include cardiac arrhythmias and seizures. Renal impairment and coma are also listed as potential severe manifestations.

Government guidance strictly mandates that immediate medical attention is required if OVERDOSE is suspected or if the patient exhibits signs of severe dehydration or significant vomiting. The patient must call a poison control center or get medical care right away.

Management focuses on general supportive measures, as no specific antidote is documented. Supportive treatment includes the replacement of fluids and the essential correction of electrolyte imbalance. This replacement is considered especially important for the elderly and the young.

Therapeutic Uses of Anara

What Anara Treats: Main Uses and Benefits

Anara is commonly used to provide short-term relief for symptoms related to delayed elimination, as described in clinical product documentation. The medication is used in conditions characterized by periods of heightened symptoms such as infrequent bowel movements, excessive straining, and the physical discomfort associated with hard, dry stools. This provides supportive relief when symptoms interfere with routine activities.

The relevant therapeutic applications include support for symptomatic relief of acute and episodic constipation and clinical assistance for bowel clearance. It is applied in clinical settings that involve supportive symptom management for colon preparation before medical procedures, such as endoscopic examinations or surgical operations. This provides supportive assistance for these interventions.

Anara contributes to easing the overall symptom load, including associated symptoms of abdominal heaviness and discomfort. This may assist with maintaining functional stability and supports patients during symptomatic phases.


Quick Fact: Relief for Functional Discomfort

The medication is considered appropriate in contexts marked by increased discomfort and tension when symptoms of difficult elimination become temporarily overwhelming.

Eligibility and Restrictions for Use

Who can and cannot use Anara?

Anara (Sodium Picosulfate) eligibility is strictly defined by regulatory agencies based on age, pre-existing health conditions, and physiological status.


Absolute Contraindications (Must Not Use)

The medicine is strictly prohibited if you have severe renal impairment (kidney function below CrCl < 30 mL/minute) or if you have acute, severe issues with your digestive tract. These include confirmed gastrointestinal (GI) obstruction, ileus, bowel perforation, toxic colitis or toxic megacolon, and severe dehydration. Use is also prohibited if you have a known hypersensitivity to the active ingredient.


Restricted Use and Limitations

Use requires caution in patients with certain cardiovascular conditions, such as congestive heart failure or those at risk of cardiac arrhythmias. Mild to moderate renal impairment also warrants caution.

Eligibility is defined by age: The medicine is approved for adults and for pediatric patients 9 years of age and older (for colon cleansing) or 10 years and older (for constipation relief). Use is not established or not recommended below these specific age thresholds.

For breastfeeding individuals, the medicine can be taken with no special precautions required. During pregnancy, use is conditional and permitted only if clearly needed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Anara (Sodium Picosulfate) is defined by its effects on gastrointestinal function and the presence of magnesium in its formulation. These interactions are formally classified in regulatory documents and require specific administration rules.


Pharmacodynamic and Absorption Interactions

Co-administration with Diuretics or Adreno-Corticosteroids may increase the risk of electrolyte abnormalities. This pharmacodynamic effect can lead to increased sensitivity to drugs like Cardiac Glycosides.

Due to accelerated intestinal transit, the absorption of many oral medications may be impaired. The label requires a time separation for these products from the start of Anara administration. Specific drugs, including Tetracycline and Fluoroquinolone antibiotics, Oral Iron Supplements, Digoxin, Chlorpromazine, and Penicillamine, require a distinct, extended separation window to prevent chelation with magnesium and subsequent reduced drug exposure.

Restrictions and Contraindications

Broad-spectrum antibiotics may reduce the laxative efficacy of the product by interfering with the colonic bacteria necessary for metabolic activation of Sodium Picosulfate. Use with other laxatives is prohibited.

Alcohol consumption and the ingestion of solid food or dairy are formally restricted during the administration period. Severe Renal Impairment (CrCl less than 30 mL/min) is a contraindication due to the officially documented risk of magnesium accumulation.

Mechanism of Action

How Anara's Prodrug Becomes Active

The drug's primary action depends entirely on a localized mechanism: the inactive Sodium Picosulfate must first travel to the colon where it is cleaved by indigenous bacterial enzymes (sulfatases) to form the active metabolite, BHPM. This essential conversion to BHPM acts as a contact stimulant, directly activating the sensory nerve endings and smooth muscle cells within the colon wall to begin the mechanistic cascade.


Dual Mechanism: Stimulating Motility and Fluid Secretion

The active BHPM engages a dual mechanism by simultaneously affecting movement and fluid dynamics. It enhances colonic peristalsis (propulsive contractions) by stimulating the enteric nervous system and increasing muscle tone. Concurrently, it modulates the colonic mucosa, promoting the secretion of electrolytes ( Cl^-, HCO3^-) and water into the lumen while inhibiting fluid absorption. This combination of accelerated propulsion and increased fluid volume produces a physiological reduction in colonic transit time.


Synergistic Action of the Combination Formula

In certain formulations, a complementary synergistic mechanism is established by combining the BHPM stimulant action with the osmotic retention of Magnesium Citrate. While BHPM actively pushes contents forward, the non-absorbable Mg^2+ ions physically draw and retain large volumes of water via an osmotic pressure gradient. This dual-action approach facilitates high internal fluidization and increased propulsion, which results in accelerated physiological expulsion of contents.

Dosage and Administration Information

Anara (Sodium Picosulfate) is indicated for oral administration across all available forms, including tablets, oral solution, and a powder for reconstitution. Clinical protocols detail two distinct usage patterns: one for short-term relief of occasional constipation and another for bowel cleansing before medical procedures.


Usage Context Dosing Pattern & Frequency Administration Specifics
Short-Term Constipation The usual adult dose starts at 5 mg and is taken once daily at night, with a maximum dose of 10 mg per day. Use should not extend beyond a short duration, typically five days. Approved for use in children 10 years of age and older.
Bowel Cleansing A mandatory two-dose regimen is required for preparation, with 10 mg of Sodium Picosulfate per dose, administered on a split-dose schedule. The second dose is taken the day of the procedure, approximately five hours prior. The powder form must be reconstituted with cold water immediately before ingestion. Consumption of mandatory additional clear liquids follows each dose; no solid food or milk is permitted from the start of the regimen.

This framework establishes that the administration of Anara is either a limited-duration, once-daily protocol focused on individual titration or a time-dependent course of therapy demanding strict fluid intake and dietary restrictions. Standard product labeling also defines specific age constraints for administration across both usage scenarios, and restricts the combination product's use in patients with severe kidney impairment.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Main Research Findings

Research has investigated the use of the drug for a specific condition. Early studies evaluated whether it could be used for this condition. Research has explored patient outcomes and changes in reported pain levels. This section describes the research findings only.


Key Clinical Studies

Study 1: Initial Efficacy and Tolerability

The initial Phase 2 trial focused on 150 adult participants over six months. The study recorded a reduction in the severity of the condition compared to the control group, and examined changes in symptoms over time. The study also documented common adverse events and participant dropout rates.

Study 2: Combination Therapy

This large-scale Phase 3 trial, involving 600 participants, examined the drug's use alongside an existing treatment. Researchers investigated the effects of the combination in different stages of the condition. Researchers conducting the study compared the drug to existing interventions, investigating whether it provides a different outcome profile.


Dosing and Administration in Trials

Protocols for the studies often involved starting the drug at a low dose and gradually increasing it based on tolerability and participant response. Different studies explored variations in dosing frequency.


Safety Profile

Studies have evaluated the safety and tolerability of the drug during long-term use in adult participants. The studies documented common adverse events and their frequency. Follow-up research continues to examine safety data.

Key Studies & References

  1. Long-Term Extension Study Assessing Safety and Tolerability of Anara Over a 24-Month Period

Frequently Asked Questions (FAQ)

Common questions about Anara (FAQ)

Q: How quickly should I expect to notice any change after starting Anara?

A: According to official product information, the medicine typically begins to work within 6 to 12 hours after it is taken. The drug is often taken in the evening when prescribed for occasional constipation, which aligns with the reported onset timeframe.


Q: How long does the main effect of Anara typically last in the body?

A: Clinical studies show that the active component of the drug, once formed, has a terminal half-life of approximately 7.4 hours. The laxative effect itself is generally seen within 6 to 12 hours.


Q: What happens if Anara is suddenly stopped or discontinued?

A: Official guidance emphasizes that use should not extend beyond a short duration, typically no more than five days, to mitigate the potential for disruption of intestinal function.


Q: How long do common initial side effects of Anara usually take to go away?

A: Minor and common side effects, such as a feeling of dizziness, headache, or tummy discomfort, are described in official documents as typically being transient. The expectation is that they are transient and may subside shortly after the medicine takes effect or as the body adjusts.


Q: Can Anara be taken at the same time as my other prescription medications?

A: Official information advises against taking other oral medications close to when you take Anara. This is because the drug accelerates transit through the intestines, which may impair the absorption of many oral medications. Official information states not to take any medicine by mouth within 1 hour before starting each dose of Anara.


Q: Does Anara interact with over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Regulatory information indicates that the absorption of many oral medications may be impaired due to accelerated intestinal transit. While specific OTC pain relievers are not named, the general advice is to separate the intake of most oral medicines from Anara.


Q: Can Anara cause changes in mood or sleep patterns?

A: The official list of adverse reactions includes sleep disorder as a commonly reported event. In rare instances, more significant neurological symptoms, sometimes including altered consciousness, have been reported.


Q: Can Anara be crushed, split, or chewed if swallowing is difficult?

A: If the medicine is in powder form, the official patient instructions require it to be dissolved in water immediately before use and must not be taken dry. If you have difficulty swallowing tablets, discuss the oral solution or powder form with a healthcare provider.


Q: Why do people sometimes misunderstand the purpose of Anara?

A: This misunderstanding often occurs because the medicine has two distinct official indications (purposes). It is used for short-term relief of occasional constipation and is also used as a mandatory part of bowel cleansing for medical procedures. The requirements for each use are very different.


Q: Is Anara used to treat anything besides the condition it was prescribed for?

A: Official labeling by regulatory bodies indicates the drug is approved only for the cleansing of the colon as a preparation for certain medical procedures and for the short-term relief of occasional constipation. No other uses are officially listed in the regulatory documents.


Q: Why did my doctor prescribe Anara instead of a different medication for my condition?

A: The drug is characterized by its dual mechanism of action, especially in its combination form. It uniquely combines a stimulant action to promote movement with the osmotic retention of fluid. This dual action is the characteristic mechanism described in official documents.


Q: Is it normal to feel a mild headache or nausea when first starting Anara?

A: Headache and nausea are listed among the most frequently reported adverse events in clinical studies. Official information indicates these are common, especially due to the powerful cleansing action.


Q: Does taking Anara affect my ability to drive or operate machinery?

A: Adverse effects such as dizziness, malaise (a general feeling of discomfort), and other neurological symptoms have been reported. Official documents note that these effects may cause impairment in a person's ability to drive or operate machinery.


Q: Is it safe to drink alcohol in moderation while using Anara?

A: Official information states that alcohol consumption is formally restricted during the administration period, especially when undergoing the bowel cleansing regimen.


Q: Can Anara interact with birth control medication?

A: While oral contraceptives are not specifically named as an interaction, the official product labeling states that the absorption of many oral medications may be impaired. This potential issue is due to the drug's effect of accelerating intestinal transit.


Q: Is it possible for Anara to become less effective over time (tolerance)?

A: Official warnings state that the medicine is only intended for short-term use. This guidance is provided because prolonged use of this type of laxative carries a risk of potentially reduced natural bowel function.


Q: What kind of patient monitoring or lab tests are usually done while taking Anara?

A: Patient monitoring, often involving blood tests to check for electrolyte abnormalities (such as low sodium or potassium), is advised by official guidance. This is particularly important for patients undergoing bowel cleansing due to the risk of severe dehydration and related complications.


Q: Does Anara affect blood sugar levels or interact with diabetes medication?

A: The product may cause severe fluid and electrolyte imbalances in the body due to its strong effect. While a direct interaction with diabetes medication is not listed, these fluid shifts may necessitate monitoring for individuals with pre-existing conditions.


Q: Is Anara available as a generic medication or only under its brand name?

A: The branded combination product's active ingredient, Sodium Picosulfate, is a well-established compound. Regulatory records show that generic versions of Sodium Picosulfate are approved and available.


Q: What percentage of people in clinical trials experienced the most common side effect of Anara?

A: Official adverse event tables categorize the frequency of side effects. The most common reactions, which include headache and nausea, are listed as 'Very Common,' meaning they affect 1 in 10 people or more.


Q: Is the active ingredient in Anara found in any other medicines?

A: Yes. The active ingredient in this medication is Sodium Picosulfate. Regulatory databases confirm that this compound is a well-established laxative found in various other drug products under different brand names and formulations.

How should Anara be stored and disposed of?

Storage Conditions and Environment

Anara (Sodium Picosulfate) must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The medicine must be protected from excessive heat and moisture; regulatory labeling explicitly states do not refrigerate or freeze the product. The container must be kept tightly closed and stored in its original packaging to preserve its integrity. All medicine must be kept out of the sight and reach of children.

Stability and Disposal

The expiration date printed on the packaging should not be exceeded. For liquid oral solutions, any unused portion must typically be discarded after a specified period following the first opening. Disposal of expired or unused medicine must be carried out in accordance with local requirements; it should not be thrown into household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anara found in:

A-Z Index: